Key clinical point: PET/CT provided accurate staging information on mantle cell lymphoma without the use of bone marrow biopsy.
Major finding: If greater than 38% of the voxels demonstrated an standard uptake value of less than 0.95, there was a sensitivity of 100% and a specificity of 80%.
Study details: A retrospective cohort study of 23 patients with mantle cell leukemia and 5 controls.
Disclosures: There was no external funding for the study and the researchers reported having no financial disclosures.
Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
This Week's Must Reads
Consider bleeding disorders in heavy menstrual bleeding, O’Brien B et al. J Pediatr Adolesc Gynecol. 2018 Nov 22 . doi: 10.1016/j.jpag.2018.11.005
Lower-dose treatment could save money in aTTP, Zwicker JI et al. ASH 2018, Abstract 374
Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5
Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491
Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1
Must Reads in Mantle Cell Lymphoma
Bortezomib plus VR-CAP looks promising in untreated MCL, Robak T et al. Lancet Oncol. 2018 Oct 19. doi: 10.1016/S1470-2045(18)30685-5
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005
First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.
Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282
Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.